Literature DB >> 12215551

Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.

Victor H Gerbaudo1, David J Sugarbaker, Scott Britz-Cunningham, Marcelo F Di Carli, Charles Mauceri, S Ted Treves.   

Abstract

UNLABELLED: Malignant pleural mesothelioma is an aggressive primary neoplasm for which early detection and accurate staging are known diagnostic challenges. The role of (18)F-FDG dual-head gamma-camera coincidence imaging ((18)F-FDG-CI) is yet to be defined. The purpose of this study was to evaluate the usefulness of (18)F-FDG-CI in the assessment of malignant pleural mesothelioma using histopathology as the gold standard.
METHODS: Fifteen consecutive patients with CT scan evidence of pleural thickening, fluid, plaques, or calcification underwent (18)F-FDG imaging 1.5 h after the intravenous administration of 370 MBq (18)F-FDG. Imaging was performed with a dual-head gamma camera equipped with 2.54-cm-thick NaI crystals operating in coincidence mode. Using an iterative algorithm, whole-body images were reconstructed as transaxial, sagittal, and coronal images. No attenuation correction was applied. The results of (18)F-FDG-CI scans were compared with CT and with histopathologic diagnosis.
RESULTS: Eleven of 15 patients had histologically proven malignant mesotheliomas (10 epithelial, 1 sarcomatoid). All 11 primary tumors were detected by (18)F-FDG, and absence of disease was confirmed in the 4 patients who were disease free. Thirty-four lesions were biopsied; among these, 29 were found to be positive for tumor. (18)F-FDG was true-positive in 28 lesions, true-negative in 4, false-negative in 1 (0.5 cm in diameter), and false-positive in 1 (inflammatory pleuritis). The smallest lesion detected was 0.8 cm. For biopsied lesions, overall sensitivity, specificity, and accuracy for (18)F-FDG-CI were 97%, 80%, and 94% respectively, compared with 83%, 80%, and 82% for CT. Twenty-one of 29 positive lesions involved the pleura, lung parenchyma, or chest wall and were all (18)F-FDG avid. In the mediastinum, (18)F-FDG-CI detected 7 of 8 biopsy-positive lesions (88%), whereas CT was positive in 6 of 8 lesions (75%). (18)F-FDG identified extrathoracic metastases in 5 patients, excluding them from surgical therapy.
CONCLUSION: These preliminary results suggest that (18)F-FDG-CI appears to be an accurate method to diagnose and to define the extent of disease in patients with diffuse malignant pleural mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215551

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Positron emission tomography in mesothelioma patients.

Authors:  Gaia Grassetto; Domenico Rubello
Journal:  Mol Imaging Biol       Date:  2009-03-25       Impact factor: 3.488

2.  FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.

Authors:  Koji Kawaguchi; Tetsuo Taniguchi; Noriyasu Usami; Takayuki Fukui; Futoshi Ishiguro; Shota Nakamura; Kohei Yokoi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-11-27

3.  Primary lesions were more 18F-FDG avid in patients with distant spread than in those without extensive disease.

Authors:  Victor H Gerbaudo; Scott Britz-Cunningham
Journal:  Mol Imaging Biol       Date:  2009 Nov-Dec       Impact factor: 3.488

Review 4.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

5.  PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.

Authors:  Andrei Fodor; Claudio Fiorino; Italo Dell'Oca; Sara Broggi; Marcella Pasetti; Giovanni Mauro Cattaneo; Luigi Gianolli; Riccardo Calandrino; Nadia Gisella Di Muzio
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

6.  FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.

Authors:  E Incerti; S Broggi; A Fodor; M Cuzzocrea; A M Samanes Gajate; P Mapelli; C Fiorino; I Dell'Oca; M Pasetti; M Cattaneo; R Calandrino; L Gianolli; N Di Muzio; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

Review 7.  Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders.

Authors:  Sandip Basu; Babak Saboury; Tom Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

8.  Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT.

Authors:  Yuyang Zhang; Jamie Edwards; Hadyn Williams; Zhonglin Hao; Samir Khleif; Darko Pucar
Journal:  Nucl Med Mol Imaging       Date:  2016-06-06

9.  FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.

Authors:  Victor H Gerbaudo; Marcelo Mamede; Beatrice Trotman-Dickenson; Hiroto Hatabu; David J Sugarbaker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

Review 10.  Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.